12:00 AM
 | 
Jul 21, 2016
 |  BC Extra  |  Company News

NICE now backs Alimta maintenance therapy

In a final draft guidance, the U.K.'s NICE recommended Alimta pemetrexed from Eli Lilly and Co. (NYSE:LLY) as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >